Changing the Practice of Medicine
Popular
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
1.00 program creditScott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Aditya Bardia, MD, MPH, FASCO
- CME/CE Broadcast Replay
A Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
1.00 creditMaria Fleseriu, MD, FACE
Shlomo Melmed, MBChB
Elise M. Brett, MD, FACE
CME/CE
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
- MinuteCE®
IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
2.00 credits 3 episodesDavid T. Rubin, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Jennifer Johnson, MD, PhD
Jennifer Johnson, MD, PhD
Clinical Practice
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- MinuteCE®
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
0.50 program creditsAdam J. Luginbuhl, MD
Adam J. Luginbuhl, MD
Jennifer Johnson, MD, PhD
Programs
- Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
David T. Rubin, MD
Michael Dolinger, MD, MBA
Enriqueta Felip, MD
Kristi Orbaugh, MSN, RNP, AOCN
David T. Rubin, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Florence Odufalu, MD
Michael Dolinger, MD, MBA